Bristol-Myers Squibb Company
IMMUNOMODULATORS

Last updated:

Abstract:

In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Status:
Application
Type:

Utility

Filling date:

21 May 2020

Issue date:

11 Aug 2022